For the second consecutive session, PVSP made higher highs and higher lows yesterday. We re-focused on this old favorite at the end of last week, and caught it trading at a low of .0014. After a solid session to close out the holiday-shortened week, we once again included it in our premarket report yesterday, and the stock kicked this week off on a strong note as well.
We observed a trading range from .0015 to .0021, a 40% intraday push, and an overall range of 50% over our observed low from Thursday.
The heathly activity on the chart can be attributed in part to last week’s acquisition news; PVSP now holds, through its newly-acquired subsidiary, a 60% stake in Denver-based distribution company servicing the hydroponic and indoor cannabis grow market>> Read PR
Plug Power, Inc. PLUG
Speaking of old favorites, PLUG has published a PR today which is standing out among this morning’s top news items, with a very promising announcement of their Q2 figures. Perhaps one of the most notable aspects; the company shipped more than twice as many of its GenDrive fuel cell units as it did in the previous quarter.
This news comes at an opportune time, with the stock having been undergoing a recent downtrend which culminated in the logging of a new 52-week low yesterday. We’re anxious to follow the activity after what is looking like a significant gap-up this morning, in what could turn into a noteworthy rebound-play.
LATHAM, N.Y., July 7, 2015 (GLOBE NEWSWIRE) — Plug Power Inc. (PLUG), a leader in providing clean, reliable energy solutions, today highlighted strong fuel cell and hydrogen infrastructure shipments and installations in the second quarter of 2015 allowing for a record revenue quarter. The company is on track to achieve its previously announced 2015 financial targets. >> FULL PR
Prima BioMed, Ltd. PBMD
Also cropping up on our news scanner this morning is PBMD. It’s no secret that we’ve had an exceptional amount of success with various pharma plays this year, and this could be the next entry into that group.
This morning’s news suggests that the company’s flagship product, a metastatic breast cancer treatment, could be on the path to approval for European markets. The stock is trading at its lowest price since May.
SYDNEY, AUSTRALIA–(Marketwired – Jul 7, 2015) – Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (“Prima” or the “Company”), a leading immuno-oncology company, is pleased to announce that it has received positive Scientific Advice from the European Medicines Agency (“EMA” or the “Agency”) on the development path for its lead product, IMP321 in metastatic breast cancer. >> FULL PR
ORMP, JDST, MDBX, KALO(Bottom-Watch), OCFN (Possible Momentum-Play)